Felix Becker1, Elvira Kurmaeva, Felicity N E Gavins, Emily V Stevenson, Aaron R Navratil, Long Jin, Ikuo Tsunoda, A Wayne Orr, Jonathan S Alexander, Dmitry V Ostanin. 1. *Department of Molecular & Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana; †Department of General and Visceral Surgery, University Hospital Muenster, Germany; ‡Department of Medicine, Center of Excellence for Arthritis and Rheumatology, Louisiana State University Health Sciences Center-Shreveport, Louisiana; Departments of §Neurology, ‖Microbiology and Immunology, ¶Cellular Biology and Anatomy; and **Pathology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana.
Abstract
BACKGROUND: Inflammation-associated lymphangiogenesis (IAL) is frequently observed in inflammatory bowel diseases. IAL is believed to limit inflammation by enhancing fluid and immune cell clearance. Although monocytes/macrophages (MΦ) are known to contribute to intestinal pathology in inflammatory bowel disease, their role in intestinal IAL has never been studied mechanistically. We investigated contributions of monocytes/MΦ to the development of intestinal inflammation and IAL. METHODS: Because inflammatory monocytes express CC chemokine receptor 2 (CCR2), we used CCR2 diphtheria toxin receptor transgenic (CCR2.DTR) mice, in which monocytes can be depleted by diphtheria toxin injection, and CCR2 mice, which have reduced circulating monocytes. Acute or chronic colitis was induced by dextran sodium sulfate or adoptive transfer of CD4CD45RB T cells, respectively. Intestinal inflammation was assessed by flow cytometry, immunofluorescence, disease activity, and histopathology, whereas IAL was assessed by lymphatic vessel morphology and density. RESULTS: We demonstrated that intestinal MΦ expressed vascular endothelial growth factor-C/D. In acute colitis, monocyte-depleted mice were protected from intestinal injury and showed reduced IAL, which was reversed after transfer of wild-type monocytes into CCR2 mice. In chronic colitis, CCR2 deficiency did not attenuate inflammation but reduced IAL. CONCLUSIONS: We propose a dual role of MΦ in (1) promoting acute inflammation and (2) contributing to IAL. Our data suggest that intestinal inflammation and IAL could occur independently, because IAL was reduced in the absence of monocytes/MΦ, even when inflammation was present. Future inflammatory bowel disease therapies might exploit promotion of IAL and suppression of MΦ independently, to restore lymphatic clearance and reduce inflammation.
BACKGROUND: Inflammation-associated lymphangiogenesis (IAL) is frequently observed in inflammatory bowel diseases. IAL is believed to limit inflammation by enhancing fluid and immune cell clearance. Although monocytes/macrophages (MΦ) are known to contribute to intestinal pathology in inflammatory bowel disease, their role in intestinal IAL has never been studied mechanistically. We investigated contributions of monocytes/MΦ to the development of intestinal inflammation and IAL. METHODS: Because inflammatory monocytes express CC chemokine receptor 2 (CCR2), we used CCR2 diphtheria toxin receptor transgenic (CCR2.DTR) mice, in which monocytes can be depleted by diphtheria toxin injection, and CCR2 mice, which have reduced circulating monocytes. Acute or chronic colitis was induced by dextran sodium sulfate or adoptive transfer of CD4CD45RB T cells, respectively. Intestinal inflammation was assessed by flow cytometry, immunofluorescence, disease activity, and histopathology, whereas IAL was assessed by lymphatic vessel morphology and density. RESULTS: We demonstrated that intestinal MΦ expressed vascular endothelial growth factor-C/D. In acute colitis, monocyte-depleted mice were protected from intestinal injury and showed reduced IAL, which was reversed after transfer of wild-type monocytes into CCR2 mice. In chronic colitis, CCR2 deficiency did not attenuate inflammation but reduced IAL. CONCLUSIONS: We propose a dual role of MΦ in (1) promoting acute inflammation and (2) contributing to IAL. Our data suggest that intestinal inflammation and IAL could occur independently, because IAL was reduced in the absence of monocytes/MΦ, even when inflammation was present. Future inflammatory bowel disease therapies might exploit promotion of IAL and suppression of MΦ independently, to restore lymphatic clearance and reduce inflammation.
Authors: L A Dieleman; M J Palmen; H Akol; E Bloemena; A S Peña; S G Meuwissen; E P Van Rees Journal: Clin Exp Immunol Date: 1998-12 Impact factor: 4.330
Authors: Li Li; Liping Huang; Sun-Sang J Sung; Amy L Vergis; Diane L Rosin; C Edward Rose; Peter I Lobo; Mark D Okusa Journal: Kidney Int Date: 2008-10-08 Impact factor: 10.612
Authors: Dmitry V Ostanin; Jianxiong Bao; Iurii Koboziev; Laura Gray; Sherry A Robinson-Jackson; Melissa Kosloski-Davidson; V Hugh Price; Matthew B Grisham Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-11-25 Impact factor: 4.052
Authors: Felix Becker; Sergey Potepalov; Romana Shehzahdi; Michael Bernas; Marlys Witte; Fleurette Abreo; James Traylor; Wayne A Orr; Ikuo Tsunoda; Jonathan Steven Alexander Journal: Inflamm Bowel Dis Date: 2015-06 Impact factor: 5.325
Authors: Felix Becker; Emily Romero; Jason Goetzmann; Dana L Hasselschwert; Beth Dray; John Vanchiere; Jane Fontenot; J Winny Yun; Paul C Norris; Luke White; Melany Musso; Charles N Serhan; J Steven Alexander; Felicity N E Gavins Journal: Am J Pathol Date: 2019-10 Impact factor: 4.307
Authors: Alan M Elder; Beth A J Tamburini; Lyndsey S Crump; Sarah A Black; Veronica M Wessells; Pepper J Schedin; Virginia F Borges; Traci R Lyons Journal: Cancer Res Date: 2018-09-25 Impact factor: 12.701
Authors: Ahmed M I Elfiky; Mohammed Ghiboub; Andrew Y F Li Yim; Ishtu L Hageman; Jan Verhoeff; Manon de Krijger; Patricia H P van Hamersveld; Olaf Welting; Iris Admiraal; Shafaque Rahman; Juan J Garcia-Vallejo; Manon E Wildenberg; Laura Tomlinson; Richard Gregory; Inmaculada Rioja; Rab K Prinjha; Rebecca C Furze; Huw D Lewis; Palwinder K Mander; Sigrid E M Heinsbroek; Matthew J Bell; Wouter J de Jonge Journal: J Crohns Colitis Date: 2022-05-10 Impact factor: 10.020